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Background. The therapeutic impact of palliative androgen deprivation in metastatic prostate cancer is indisputable. Bilateral
orchiectomy represents the traditional method of AD but was reduced during the last years in favor for treatment with LHRH
analogues. Due to limited economic resources of the health care system, the economically priced deﬁnite surgical castration might
experience a renaissance. Methods. In this single-center retrospective study, 83 consecutive patients with osseous metastasized
prostate cancer were evaluated, who had primarily been treated by subcapsular bilateral orchiectomy. Response to therapy, time
until therapy failure, overall survival time, psychological disorders due to loss of organ, and disease-associated and postoperative
surgical complications were recorded. The median followup was 35 months (IQR: 26–46). Results. Patients’ mean age at surgery
was 72.1 (54–91) years. Six patients (7.2%) displayed immediate tumor progression after orchiectomy. Median time of tumor
remission and overall survival time were 29 and 36 months, respectively. 14% of the study group showed minor postoperative
complications. No psychological problems occurred following bilateral orchiectomy. Conclusion. Due to an eﬀective and persistent
oncological eﬀectiveness, less morbidity, and absence of psychological implications, bilateral subcapsular orchiectomy seems to be
a practicable and advisable alternative in the ﬁrst-line therapy of metastasized PCa.
1.Introduction
In the pre-PSA era, one third of men with prostate cancer
(PCa) presented with distant metastasis at time of diagnosis,
andcurrently,itisabout5%–10%[1].Despitethesechanges,
PCa still represents the second most frequent tumor-associ-
ated cause of death. In 2006, 12000 men died from PCa in
Germany [1].
Suppression of endocrine testicular function still repre-
sents the gold standard in palliative treatment in advanced
stage or metastasized PCa. Already in 1941, Huggins and
Hodges demonstrated control of PCa growth rate by andro-
gensandshowedthatthereisnobetterwaytoachievetempo-
rary control of PCa growth than androgen deprivation (AD)
[2]. Basically, AD treatment is able to induce a remission in
90% of PCa patients; the median progression-free survival
ranges from 18 to 34 months [3].
The earliest method of AD is represented by the bilateral
orchiectomy, which means a deﬁnitive therapy for the pa-
tient.TreatmentwithDiethylstilbestrol(DES)wasde-scribed
as to the ﬁrst method of reversible castration. At present,
medicinal castration is achieved either by LHRH analogues,
which have been available since the 1980s or by GnRH
antagonists being approved at the end of the last decade.
The use of antiandrogens remains the limitation of initial
increaseoftestosterone(ﬂarephenomenon)undertreatment
with LHRH analogues. Alternatively, they can also be used as
monotherapy, especially in patients with marginal metastatic
load with consideration of a better quality of life but only
slightly shorter progression-free and overall survival in
comparison to castration [4].
Despite the fact that bilateral orchiectomy represents a
proven method showing excellent oncological eﬃciency with2 Advances in Urology
rapidonsetofaction,100%complianceofsurgicalcastration
due to the deﬁnite character, and just minimal side eﬀects,
at present, priority is given to medical treatment [5]. One
rational explanation for the avoidance of surgical castration
might be the expectation of psychological consequences due
to loss of testicles [6]. In 1942, Riba described subcapsular
bilateral orchiectomy (OE-R) as a surgical method of avoid-
anceofthe“emptyscrotum”withoutdamageoftheoncolog-
ical eﬀectiveness [7]. Furthermore, American and European
studies could clearly prove that medical castration by LHRH
analogues is considerably more expensive than surgical
castration [8, 9].
In the present retrospective study, 83 patients with an
osseous metastasized adenocarcinoma of the prostate under-
going OE-R in an 11-year period were analyzed with respect
toprogression-freeandoverallsurvivalanddiscussedagainst
the background of internationally available data on this
topic. Furthermore, disease-related and postoperative surgi-
cal complications as well as psychological implications were
evaluated and discussed.
2. Methods
In the time period between January 1990 and December
2000, OE-R was carried out in 98 patients with a metas-
tasized PCa in the clinical center Berlin-Moabit. Based on
electronic patient ﬁles of the hospital and from urologists in
practice, clinical and oncological parameters of 83 patients
with bone metastasis, out of whom 63% presented with
multiple metastases, could be evaluated. In two out of 15
patients excluded, examination criteria were not completely
documented, and in further 13 patients, the OE-R was not
accomplished as primary therapy for osseous metastasized
PCa. Accurate assessment of PSA kinetics (initial value and
nadir) could be evaluated in 67 patients. Patients were
oﬀered OE-R in local anesthesia, and surgery was carried
out according to the originally published surgical method
[7]. Each patient received antibiotic single-shot application
at the day of surgery. In all cases, postoperative pain could be
managed with nonsteroidal anti-inﬂammatory drugs.
Oncologic course of disease was calculated by Kaplan-
Meier method according to time of tumor remission and
overall survival starting at the moment of OE-R. For the
determination of the time until tumor remission, patients
who died without tumor progression were censored by time
of death. In 16 patients, preoperative PSA values were not
known; however, following PSA values were assessed so that
even in these patients the end of hormonal sensitivity could
be deﬁned by an increase of the PSA value and/or by newly
established symptoms. The median followup was 35 months
(IQR: 24–26).
Psychologically relevant disorders of the patient caused
by loss of testicles were considered when information of
psychological problems was indicated by the patient himself
(criteria 1), in case of comedication with antidepressant
drugs (criteria 2), or cotreatment by a psychiatrist (criteria
3). Information on this was taken by the electronic patient
ﬁles noted by the ambulant urologist. Criteria 1 was proven
by the ambulant urologist with the question: “Do you feel
compromised in your well-being or body consciousness due
to cosmetic or optical consequences caused by the opera-
tion?”.
3. Results
3.1.Patients’Demography. Averageageofpatientsatthetime
of OE-R was 72.1 (54–91) years, and general condition of
patients according to ECOG criteria was median 0 (n = 41;
49.4%). Altogether 17 patients (20.5%) showed an ECOG
performance status of ≥2. In all cases, histologically aﬃrmed
adenocarcinoma of the prostate was present. 70% (n = 58)
of patients had an undiﬀerentiated tumor (solitary Gleason
pattern: ≥4). In 67 patients, preoperative PSA value was
known, and the median value was 144ng/mL (IQR: 68–
259). In 9.6% patients (n = 8), AD primarily resulted in
achievement of maximum hormone blockade (OE-R plus
antiandrogen).
3.2. Operation Parameter. In 62 patients (74.7%), OE-R was
performed in local anesthesia. The remaining 21 patients
additionally received sedoanalgesia. Representing a surgical
procedure mostly performed by residents (n = 74), the op-
eration time was 25 minutes (11–47 minutes) with a median
of 20 minutes.
Altogether, 12 postoperative complications (14.4%) were
described, which were managed conservatively in 7 cases
(3x hematoma and 4x wound infection). In 5 patients, sur-
gical revision (2x massive hematoma and 3x abscess) was
necessary.
3.3. Oncological Followup. Median time of hormonal eﬃ-
cacy was 29 months, whereby 11% of patients (n = 9)
showed tumor remission until 5 years beginning from OE-R
(Figure 1). Median overall survival of 36 months was an-
alyzed. After 5 years, 16% (n = 13) of the patients were
still alive. The mean PSA nadir achieved was 10.5 (0.01–
212)ng/mL, but 45% patients (n = 37) achieved a PSA
nadir under 2ng/mL. Six patients (7.2%) showed immediate
tumor progression after OE-R. Seven patients of the study
group (8.4%) underwent chemotherapy for further treat-
ment during castration-resistant status (diﬀerent protocols,
n = 4 with Mitoxantrone 12mg/m2 q3w).
During further disease progression, 12% of patients suf-
fered from pathologic bone fractures (n = 10). According to
electronicpatientﬁlesreceivedfromtheambulanturologists,
there was no patient with psychological problems (criteria
1–3, Section 2) concerning OE-R. More than one half of pa-
tients (n = 48, 58%) declared to suﬀer psychologically under
general consequences of androgen withdrawal (disturbances,
depression, tiredness, muscle wasting, osteoporosis, loss of
libido, and erectile dysfunction).
4. Discussion
In 1895, White demonstrated the hormone sensibility of the
prostate by treating 111 men with an obstructive prostateAdvances in Urology 3
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Figure 1: Time of tumor remission in 83 patients with
osseous metastasized prostate cancer after subcapsular orchiectomy
(Kaplan-Meier method).
hyperplasia by surgical castration [10]. In 1935, David et al.
succeeded in isolating testosterone. Subsequently, Huggins
and Hodges inaugurated the androgen deprivation as tar-
geted therapy in advanced PCa [2]. For several decades,
surgical castration displayed the gold standard in metasta-
sized PCa. Huggins received the Nobel Prize for Medicine
and Physiology in 1966 in appreciation of his scholarly
achievements. Coy et al. and Labrie et al. ﬁrst synthesized
potent LHRH analogues in 1973. This new substance class
has eﬀectively been applied since the 1980s as standard
therapy in metastasized PCa [11, 12].
Equivalence of surgical and medical castration with
regard to remission and overall survival rate has been veriﬁed
suﬃciently [13, 14]. Median time of tumor remission in the
present study was 29 months, which was in the upper range
of the corresponding expectation values for PCa patients
with primary AD therapy in tumor stage D2 [15].
Oneadvantageoforchiectomyisrapideﬀectiveness,with
achievement of castration level between 3 to 12 hours post-
operatively [16]. This is an extremely important factor for
symptomatic patients (ostealgia, imminent fracture, and
compression of the spinal cord). A compromise of the onco-
l o g i c a ls a f e n e s sw i t hO E - Ri sn o tam a t t e ro fc o n c e r nd u e
to potential residual of testicular parenchyma. Postsurgical
testosterone and LH level is comparable with values after
bilateral radical orchiectomy [17, 18].
A second advantage is the deﬁnitive approach of surgical
castration with respect to good compliance of patients.
A disadvantage might occur when intermittent androgen
deprivation (IAD) would be indicated [19]. In the basic
studies, Goldenberg et al. added this form of therapy hoping
for improvement of quality of life during the therapy-free
intervalandaltogetherforaprolongeddurationoftreatment
during hormone sensitive status [20]. A large clinical study
comparingacontinuouswithintermittentAD(SWOG9346)
showed no diﬀerence in overall survival [21]. In a recent
study (SEUG), there was no evidence of better survival or
an improvement of quality of life for IAD in comparison to
continuous AD [22].
In 14% of patients in the present study, surgical side
eﬀectsoccurred;however,inonly5patients,surgicalrevision
was necessary. This high postoperative complication rate in
comparison to an international level might eventually be
based on the fact that in our study, the OE-R was mainly
performed by residents (89%). Orchiectomy and the use of
LHRH analogues or GnRH antagonists did only show slight
diﬀerences concerning other side eﬀects [23]. Hot ﬂushes,
lack of drive, loss of libido, and erectile dysfunction are
the major side eﬀects of castration therapy which were
reported by patients. In our study group, 58% of patients
suﬀered from psychical illness. In the long-time period,
in approximately 50% of patients, osteoporotic changes
occurred. In case of that, there seems to be a rationale to
applysimultaneoustherapywithbisphosphonatesorRANK-
ligand-inhibitors (Denosumab) [24, 25]. Due to the fact that
prostate cancer mainly metastasizes into bones, a prevention
of pathologic fractures is expected by the use of this co-
medication.
A psychological strain caused by loss of testicles was not
detectable in our study group (in accordance with criteria
1–3). Regarding this, a representative study by the Zoladex
Prostate Cancer Group Study was initiated which compared
quality of life and psychological status of patients with med-
ical versus surgical castration [26]. In this study, including
147 PCa patients at tumor stages D1-D2 (Zoladex 115 and
orchiectomy 32), patients were able to individually choose
the kind of therapy, and, ﬁnally, an advantage was observed
intheZoladexarmconcerningqualityoflifeandpsychologi-
cal status. Especially in the sector of body awareness, patients
with surgical castration reported detriment [26]. However,
there are also studies with best evidence which report no
diﬀerence in “body image” and “quality of life” between
both treatmentarms[27]. In the “Prostate Cancer Outcomes
Study,” there was signiﬁcantly more gynecomastia (25%
versus 10%) and a reduced general health condition (35%
versus 28%) by treatment with LHRH analogues compared
to patients with surgical orchiectomy [28]. Furthermore,
patients taking LHRH analogues critically described to feel
more often reminded of their treatment and their cancer
disease. Due to this, they felt a negative impact in quality of
life [28].
Concerning the general worse assigned body image of
patientswithorchiectomy,whichiscausedbylossoftesticles,
the paper of Issa et al. should be taken into consideration
[29]. In this study on 88 orchiectomized patients pretreated
by LHRH analogues (n = 52), the weight of testicles in study
group 1 was compared with study group 2, comprising pa-
tients undergoing orchiectomy without medical pretreat-
ment(n = 36).Therewasasigniﬁcantlylowermedianweight
of testicles in patients with pretreatment (7 versus 15gr.;
P<0.001) [29]. In consideration of volume-protecting4 Advances in Urology
eﬀects after the surgical method described by Riba (OE-R),
general data concerning deprivation of body awareness in
patients after orchiectomy in comparison to medical cas-
trated patients have to be interpreted more cautiously. In
one study, Chadwick et al. showed that approximately 50%
of men with advanced prostate cancer would have chosen
orchiectomy if they had been oﬀered this as a therapeutic
option [30]. Furthermore, there is an extremely insightful
study of Mariani et al., which again documents that 70% of
patients with free option of treatment would choose LHRH
analogue treatment [31]. However, in case of 20% self-
maintenance in therapy costs, only 24% of patients would
favor medical hormonal ablation [31].
Each study assessing cost eﬃciency of therapy clearly
aﬃrmed an advantage for orchiectomy in comparison to
medical castration. Even older studies, that are describing
deﬁnitelylongerperiodsofhospitalizationafterorchiectomy,
agree with this statement [32, 33]. In the study of Mariani
et al. which already has been quoted, 96 patients were an-
alyzed. Treatment with LHRH analogues was assessed to
be 10.7x to 13.5x more expensive than surgical castration
[31]. Deliberations concerning treatment should include the
limited ﬁnancial valences of the public health system, con-
sidering that in case of equality of treatment eﬀects, an in-
adequate resource policy would be short-sighted and, fur-
thermore, limit treatment options for other patients.
The present study shows some limitations, which have to
be considered with regard to interpretation of the results. It
is a retrospective study based on a limited number patients
included in the study group (only 8 patients were added
per year), who have been treated during a relatively long
time span and by diﬀerent surgeons. Period of examination
(1990–2000)tookplacebeforetheapprovalofDocetaxel;this
mightbeoneofthereasonsfortheworsemedianoverallsur-
vival (35 months). Lacking availability of chemotherapy on
the basis of evidence recommendation during the evaluation
period, only 8% of patients were treated with chemotherapy
at castration-resistant tumor stage (CRPC). Most patients
onlyreceivedbestsupportivecare.Inadditiontothat,onlyin
81% of patients, the preoperative PSA values were known. It
has to be critically noted that the evaluation of psychological
disorders, caused by loss of testicles, was not determined
based on standardized and validated questionnaires.
In summary, the present study shows that subcapsular
bilateral orchiectomy described by Riba (OE-R) remains a
very eﬀective procedure with few side eﬀects in the primary
treatmentofmetastaticPCa.Thisprocedurecombinesahigh
patientcomfortwiththeabsenceofmentaldisordersandlow
costs for a ﬁnancial limited public health system.
5. Conclusions
Against the background of cost explosion in the health care
system, OE-R might experience a renaissance as an eﬀective
therapeutic option of androgen deprivation and as a cost-
eﬀective method with only few side eﬀects. Hence, OE-R
could regain an increasing relevance in the primary therapy
of metastasized PCa.
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